Aurora Cannabis (ACB) Expected to Post Earnings on Wednesday

Aurora Cannabis (NASDAQ:ACB) will likely be posting its Q1 2027 results before the market opens on Wednesday, August 5th. Analysts expect Aurora Cannabis to post earnings of ($0.13) per share and revenue of $47.45 million for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2027 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Aurora Cannabis (NASDAQ:ACB) last posted its quarterly earnings results on Thursday, June 11th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.14. Aurora Cannabis had a negative net margin of 33.57% and a positive return on equity of 0.10%. The business had revenue of $60.98 million during the quarter, compared to the consensus estimate of $54.42 million. On average, analysts expect Aurora Cannabis to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Aurora Cannabis Stock Performance

Shares of NASDAQ ACB opened at $2.79 on Monday. Aurora Cannabis has a fifty-two week low of $2.56 and a fifty-two week high of $6.66. The firm has a market capitalization of $172.81 million, a P/E ratio of -1.79 and a beta of 0.58. The company has a debt-to-equity ratio of 0.04, a current ratio of 5.94 and a quick ratio of 3.32. The company’s 50 day simple moving average is $2.96 and its 200 day simple moving average is $3.39.

Analyst Upgrades and Downgrades

ACB has been the topic of a number of recent analyst reports. Wall Street Zen upgraded Aurora Cannabis from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings upgraded shares of Aurora Cannabis from a “sell (d-)” rating to a “sell (d)” rating in a research report on Tuesday, June 16th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold”.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ACB. State of Wyoming increased its holdings in shares of Aurora Cannabis by 10.5% in the second quarter. State of Wyoming now owns 23,722 shares of the company’s stock worth $101,000 after acquiring an additional 2,246 shares in the last quarter. Mackenzie Financial Corp lifted its holdings in shares of Aurora Cannabis by 15.0% during the 3rd quarter. Mackenzie Financial Corp now owns 33,909 shares of the company’s stock valued at $202,000 after purchasing an additional 4,422 shares in the last quarter. TD Asset Management Inc grew its position in shares of Aurora Cannabis by 7.6% in the 4th quarter. TD Asset Management Inc now owns 78,255 shares of the company’s stock valued at $329,000 after purchasing an additional 5,520 shares during the period. Northwestern Mutual Wealth Management Co. grew its position in shares of Aurora Cannabis by 1,808.9% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,518 shares of the company’s stock valued at $63,000 after purchasing an additional 9,967 shares during the period. Finally, Headlands Technologies LLC bought a new stake in Aurora Cannabis during the 4th quarter worth approximately $58,000. 47.63% of the stock is currently owned by institutional investors.

About Aurora Cannabis

Aurora Cannabis Inc (NASDAQ: ACB) is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada’s regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country’s largest growers by cultivation capacity and production output.

The company’s core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments.